Explore the vast range of titles available.

The use of deployable structures has a wide range of applications nowadays. They can be transformed from a closed compact configuration to a predetermined expanded form, in which they are stable and can carry loads. This article describes a sort of deployable structure that has been patented by researchers of two Spanish institutions: San Pablo CEU University and Eduardo Torroja Institute. Geometric aspects are key to accomplish an efficient folding and unfolding procedure along with an optimum structural behavior when the structure is deployed. Tensioned cables are essential in these structures. The main goal is to make the cable acquire its maximum length when the structure is fully deployed. This will avoid complex operations of post-tensioning in order to make the cable perform its function.

The generation of mobile charges and their transport across organic layers are commonly the most critical steps affecting the performance of organic-based electronic devices. At ambient temperatures, intermolecular hopping of self-localized charge carriers is expected to dominate the transport mechanism, whose properties can be accurately described by quantum-chemical calculations which, however, face a challenge when the nanostructure of the material has to be simultaneously addressed together with single-molecule aspects. Our recent work tries to understand the physico-chemical principles behind the performance of the theoretical methods commonly employed, as well as to pave the way towards full understanding of the transport mechanism by applying optimized theoretical methods. This would finally allow the performance of computationally guided molecular engineering of novel molecules, not yet synthesized, and anticipate the reasons for their expected performance in organic-based electronic devices.

Guidelines recommend autologous stem cell transplantation (ASCT) consolidation in first complete or partial response after regimens including rituximab (R) and high-dose AraC (HDAC), but its use beyond that response is questioned. We present a retrospective analysis of 268 patients with MCL who received ASCT. With a median follow-up for survival patients of 54 months, progression-free survival and overall survival for the whole series were 38 and 74 months, respectively, and for patients transplanted in first CR 49 and 97 months, respectively. Patients without CR before transplant were analyzed separately, those who achieved CR after transplantation had better PFS (48 vs 0.03 months, p  < 0.001) and OS (92 vs 16 months, p  < 0.001) than the remaining. In univariate analysis, first CR at transplant ( p  = 0.01) and prior rituximab ( p  = 0.02) were the variables associated with PFS. For OS, the same variables resulted significant ( p  = 0.03 and p  < 0.001, respectively). In multivariate analysis, only the status at transplant (first CR) remained significant. This retrospective study concludes that ASCT consolidation in first CR induces high survival rates. In other stages of disease, the need of ASCT as consolidation may be questioned.

Naive T cell activation requires signaling by the T cell receptor and by nonclonotypic cell surface receptors. The most important costimulatory protein is the monovalent homodimer CD28, which interacts with CD80 and CD86 expressed on antigen-presenting cells. Here we present the crystal structure of a soluble form of CD28 in complex with the Fab fragment of a mitogenic antibody. Structural comparisons redefine the evolutionary relationships of CD28-related proteins, antigen receptors and adhesion molecules and account for the distinct ligand-binding and stoichiometric properties of CD28 and the related, inhibitory homodimer CTLA-4. Cryo-electron microscopy–based comparisons of complexes of CD28 with mitogenic and nonmitogenic antibodies place new constraints on models of antibody-induced receptor triggering. This work completes the initial structural characterization of the CD28–CTLA-4–CD80–CD86 signaling system.

Chronic obstructive pulmonary disease (COPD) is expected to be the 3.sup.rd leading cause of death worldwide by 2020. Despite improvements in survival by using acute non-invasive ventilation (NIV) to treat patients with exacerbations of COPD complicated by acute hypercapnic respiratory failure (AHRF), these patients are at high risk of readmission and further life-threatening events, including death. Recent studies suggested that NIV at home can reduce readmissions, but in a small proportion of patients, and with a high level of expertise. Other studies, however, do not show any benefit of home NIV. This could be related to the fact that respiratory failure in patients with stable COPD and their response to mechanical ventilation are influenced by several pathophysiological factors which frequently coexist in the same patient to varying degrees. These pathophysiological factors might influence the success of home NIV in stable COPD, thus long-term NIV specifically adapted to a patient's \"phenotype\" is likely to improve prognosis, reduce readmission to hospital, and prevent death. In view of this conundrum, Rescue2-monitor (R2M), an open-label, prospective randomized, controlled study performed in patients with hypercapnic COPD post-AHRF, will investigate the impact of the quality of nocturnal NIV on the readmission-free survival. The primary objective is to show that any of 3 home NIV strategies (\"rescue,\" \"non-targeted,\" and \"targeted\") will improve readmission-free survival in comparison to no-home NIV. The \"targeted\" group of patients will receive a treatment with personalized (targeted) ventilation settings and extensive monitoring. Furthermore, the influence of comorbidities typical for COPD patients, such as cardiac insufficiency, OSA, or associated asthma, on ventilation outcomes will be taken into consideration and reasons for non-inclusion of patients will be recorded in order to evaluate the percentage of ventilated COPD patients that are screening failures. ClinicalTrials.gov NCT03890224. Registered on March 26, 2019.